Pharmacology, Toxicology and Pharmaceutical Science
Fibrinolytic Agent
98%
Tissue Plasminogen Activator
63%
Plasminogen Activator
54%
Fibrinogen
52%
Plasminogen Activator Inhibitor 1
47%
Thrombin
37%
Inflammation
35%
Diabetes Mellitus
34%
Anticoagulant Agent
34%
Ischemic Heart Disease
31%
Heart Infarction
31%
Thrombosis
30%
Insulin Dependent Diabetes Mellitus
25%
Hemostatic Agent
25%
C Reactive Protein
25%
Oral Contraceptive
24%
Plasminogen
23%
Prothrombin
22%
Placebo-Controlled Study
22%
Heparin
22%
Blood Clotting Factor 12
21%
Bleeding
20%
Thromboplastin
19%
Alteplase
19%
Blood Clotting Factor 7
19%
Venous Thromboembolism
19%
Replacement Therapy
18%
D Dimer
18%
Plasmin
17%
Von Willebrand Factor
16%
Cardiovascular Risk
16%
Placebo
16%
Cardiovascular Disease
15%
Cohort Study
15%
Gliclazide
15%
Biological Marker
15%
Acute Heart Infarction
15%
Protein C
14%
Plasminogen Activator Inhibitor
14%
Albumin
13%
Triacylglycerol
13%
Complement Component C1s Inhibitor
13%
Urokinase
12%
Antivitamin K
12%
Klinefelter Syndrome
12%
Ethinylestradiol
12%
Antithrombin III
12%
Atrial Fibrillation
12%
Dabigatran
12%
Coagulating Agent
11%
Non Insulin Dependent Diabetes Mellitus
11%
Deep Vein Thrombosis
10%
Cerebrovascular Accident
10%
Heart Disease
10%
Blood Clotting Factor
10%
Prospective Study
10%
Fibrin Degradation Product
10%
Antiplasmin
9%
Warfarin
9%
Protein S
9%
Gestodene
9%
Procoagulant
9%
Leporidae
9%
Troponin
9%
Coumarin
8%
Vascular Disease
8%
Prekallikrein
8%
Blood Stasis
8%
Tissue Factor Pathway Inhibitor
8%
Enzyme-Linked Immunosorbent Assay
8%
Antithrombin
8%
Insulin Resistance
7%
Chronic Obstructive Lung Disease
7%
Androgen
7%
Diseases
7%
Angina Pectoris
7%
Hypovitaminosis D
7%
Activated Protein C
7%
Atherosclerosis
7%
Kidney Disease
7%
Alpha 2 Macroglobulin
7%
Clinical Trial
6%
Diabetic Nephropathy
6%
Dimer
6%
Traumatic Brain Injury
6%
Hyperlipidemia
6%
Lung Embolism
6%
Normal Human
5%
Contraceptive Agent
5%
Vitamin K Group
5%
Randomized Controlled Trial
5%
Streptokinase
5%
Levonorgestrel
5%
Vein Thrombosis
5%
Alpha 2 Antiplasmin
5%
Low Dose Oral Contraceptive
5%
Interleukin 6
5%
Postoperative Hemorrhage
5%
Plasminogen Activator Inhibitor 2
5%
Brain Ischemia
5%
Medicine and Dentistry
Fibrinolysis
100%
Tissue Plasminogen Activator
50%
Fibrinogen
45%
Plasminogen Activator Inhibitor-1
40%
Plasminogen Activator
39%
Hemostat
33%
Thrombosis
28%
Thrombin
26%
Cardiovascular Disease
25%
C Reactive Protein
24%
Diabetes Mellitus
22%
Ischemic Heart Disease
21%
Klinefelter Syndrome
21%
Randomized Controlled Trial
20%
Bleeding
20%
D-Dimer
20%
Insulin Dependent Diabetes Mellitus
19%
Blood Clotting
18%
Fibrin Clot
18%
Oral Contraceptive
18%
Venous Thromboembolism
16%
Von Willebrand Factor
16%
Antithrombotic
16%
Endothelial Cell
16%
Factor VII
15%
Roux-en-Y Gastric Bypass
14%
Endothelial Function
14%
Body Mass Index
14%
Placebo
14%
Biological Marker
13%
Blood Stasis
13%
Cohort Analysis
13%
Triacylglycerol
13%
Cardiovascular Risk
12%
Plasminogen Activator Inhibitor
12%
Diseases
12%
Complement Component C1s Inhibitor
11%
Diabetic Nephropathy
11%
Heparin
11%
Albumin
11%
Deep Vein Thrombosis
10%
Bariatric Surgery
10%
Meta-Analysis
10%
Cardiovascular System
10%
Apoplexy
10%
Sex Difference
10%
Gastric Bypass Surgery
10%
Orthognathic Surgery
10%
Androgen
10%
Hip Fracture
10%
Procoagulant
9%
Atrial Fibrillation
9%
Anticoagulation
9%
Prothrombin
9%
Nephropathy
9%
Diabetes
9%
Androgen Therapy
8%
Thromboplastin
8%
Phlebothrombosis
8%
Maturity Onset Diabetes of the Young
8%
Substitution Therapy
8%
Contraceptive Agent
8%
Coagulating Agent
8%
Plasminogen
8%
Anticoagulant
8%
Hypogonadism
8%
Brain Ischemia
7%
Supplementation
7%
Randomized Clinical Trial
7%
Tranexamic Acid
7%
Prevalence
7%
Polycystic Ovary Syndrome
7%
Transurethral Resection
7%
Gastric Bypass
7%
Pre-Eclampsia
7%
Ischemic Preconditioning
7%
Hypovitaminosis D
7%
Placebo-Controlled Study
7%
Heart Disease
7%
Monounsaturated Fatty Acid
7%
Factor XII
7%
Plasminogen Activator Inhibitor-2
7%
High Fat Food
7%
Insulin Resistance
7%
Myocardial Infarction
7%
Dimer
7%
Patient with Type 2 Diabetes
6%
Prospective Study
6%
Antithrombin III
6%
Disease
6%
Atherosclerosis
6%
Heart Muscle Injury
6%
Emergency Department
6%
Interleukin 6
6%
Vitamin K Antagonist
6%
Cell Function
6%
Antithrombin
6%
Fibrin Metabolism
6%
Protein C
6%
Coronary Artery Disease
6%
Biochemistry, Genetics and Molecular Biology
Fibrinolysis
65%
Blood Plasma
62%
Fibrinogen
59%
Tissue Plasminogen Activator
45%
Plasminogen Activator Inhibitor-1
34%
Plasminogen Activator
33%
Blood Level
29%
Klinefelter Syndrome
24%
C1-Inhibitor
18%
Thrombin
18%
Protein C
16%
Factor VII
15%
Genetics
14%
Body Mass
14%
C-Reactive Protein
13%
Fibrinolysin
13%
Plasmin
13%
Genotyping
13%
Triglyceride
13%
Anticoagulation
13%
Fibrin Clot
12%
Antithrombin
12%
Kallikrein
12%
D-Dimer
11%
Enzyme
11%
Allele
11%
Thromboplastin
11%
Cohort Study
10%
Factor XII
10%
Prekallikrein
10%
Glycoprotein
10%
Deep Vein Thrombosis
10%
Leporidae
10%
Blood Clot Lysis
9%
Protein S
9%
Ethinyl Estradiol
9%
Fibrin Formation
9%
Coagulation System
8%
Prospective Study
8%
Blood Coagulation Factor
8%
Cross Sectional Study
8%
Fibrinogen Blood Level
8%
Macroglobulin
8%
Insulin Resistance
8%
Phlebothrombosis
8%
Cholesterol Blood Level
7%
Urokinase
7%
Hereditary Angioedema
7%
Von Willebrand Factor
7%
Hemostasis
7%
Alpha-2-Macroglobulin
7%
Troponin
7%
Histidine
7%
Insulin Level
7%
Fibrin Degradation Product
7%
Lipid
6%
Blood Lipids
6%
Circadian Rhythm
6%
Cardiac Troponin
5%
Glucose Blood Level
5%
HDL-Cholesterol
5%
Kininogen
5%
Prevalence
5%
Low Drug Dose
5%
Protease
5%
Lipoprotein
5%
Plasminogen Activator Inhibitor-2
5%
Case-Control Study
5%
Genetic Divergence
5%
Insulin Sensitivity
5%
Sex Difference
5%
Alpha 2-Antiplasmin
5%
Thrombocyte Aggregation
5%
XYY Syndrome
5%
Hypovitaminosis D
5%